As of March 31, 2025, cash, cash equivalents and marketable securities totaled $197.9 million compared to cash, cash equivalents and marketable securities of $231.5 million as of December 31, 2024. The decrease in cash is related to funding ongoing operations. Cash is expected to support current clinical and operational activities into early 2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS:
- Acumen presented results from pTau217 assay in Phase 2 ALTITUDE-AD trial
- Acumen Pharmaceuticals’ Earnings Call: Progress Amid Challenges
- Acumen Pharmaceuticals’ Promising Alzheimer’s Strategy Earns Buy Rating with Revised Price Target
- Acumen price target lowered to $11 from $15 at H.C. Wainwright
- Acumen price target lowered to $10 from $12 at BofA